Orthofix Medical Inc. (OFIX)
| Market Cap | 496.18M -13.6% |
| Revenue (ttm) | 822.31M +2.9% |
| Net Income | -92.19M |
| EPS | -2.33 |
| Shares Out | 40.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 83,908 |
| Open | 12.31 |
| Previous Close | 12.35 |
| Day's Range | 12.31 - 12.60 |
| 52-Week Range | 10.24 - 16.99 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 17.25 (+39.56%) |
| Earnings Date | May 5, 2026 |
About OFIX
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graf... [Read more]
Financial Performance
In 2025, Orthofix Medical's revenue was $822.31 million, an increase of 2.85% compared to the previous year's $799.49 million. Losses were -$92.19 million, -26.83% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for OFIX stock is "Buy." The 12-month stock price target is $17.25, which is an increase of 39.56% from the latest price.
News
Orthofix Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Orthofix Medical, Inc. - OFIX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced...
Orthofix to Report First Quarter 2026 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2026 financial results on T...
Orthofix Realigns Spine Leadership to Strengthen Focus and Execution
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced a strategic realignment of its Spine leadership team designed to a...
Halper Sadeh LLC Encourages Orthofix Medical Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breached their fiduciary dutie...
OFIX Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Orthofix Medical Inc. – OFIX
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Orthofix Medical Inc...
Orthofix Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Orthofix Medical, Inc. – OFIX
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Orthofix Medical Inc...
Orthofix Medical Transcript: TD Cowen 46th Annual Health Care Conference
Leadership transformation and commercial realignment have driven margin expansion and set the stage for multi-year growth, with over a dozen product launches and a focus on high-value segments. Financial targets include 6.5%-7.5% sales CAGR and mid-teens EBITDA margin by 2028.
Orthofix Medical Transcript: 2026 CG Musculoskeletal Conference
Strong operational progress and financial discipline led to growth across all segments, with channel optimization and innovation driving future momentum. U.S. limb reconstruction is a major growth focus, while 7D technology and biologics see renewed investment. Long-range goals were extended to 2028 to fully realize channel upgrades.
Orthofix Medical Earnings Call Transcript: Q4 2025
Delivered strong Q4 and full-year growth in BGT, limb reconstruction, and spine, with margin expansion and robust free cash flow. 2026 guidance calls for 5.5% sales growth, higher EBITDA, and positive free cash flow, supported by new product launches and a strengthened distributor network.
Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended De...
Orthofix to Participate in Upcoming Investor Conferences
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and...
Orthofix to Report Fourth Quarter and Full-Year 2025 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2025 financi...
Orthofix Medical Transcript: Stifel 2025 Healthcare Conference
Q3 results exceeded expectations with strong U.S. spine and orthopedics growth, driven by innovation, distributor consolidation, and new product launches. Margin expansion initiatives and a robust product pipeline, including Virata, position the business for accelerated growth and profitability through 2027.
Orthofix Medical Transcript: UBS Global Healthcare Conference 2025
The company has transformed its financial base, achieved sustained EBITDA growth, and is launching innovative products like Vertabra and TruLock Elevate. Strategic distributor consolidation, disciplined R&D, and a focus on high-margin markets support long-term growth targets.
Orthofix Medical Earnings Call Transcript: Q3 2025
Strong Q3 results featured 6% revenue growth, margin expansion, and robust U.S. spine and orthopedics performance. Guidance for 2025 was narrowed with higher EBITDA expectations, and new product launches and distributor strategies are set to drive future growth.
Orthofix Reports Third Quarter 2025 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 202...
Orthofix to Report Third Quarter 2025 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2025 financial results on T...
Orthofix Medical Earnings Call Transcript: Q2 2025
Q2 2025 net sales rose 4% year-over-year to $200.7M, with strong margin expansion and positive free cash flow. U.S. orthopedics and enabling technologies drove growth, while new product launches and distributor transitions are expected to sustain momentum.
Orthofix Reports Second Quarter 2025 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2025, a...
Orthofix to Participate at Canaccord Genuity 45th Annual Growth Conference
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate at the Canaccord Genuity 45th An...
Orthofix to Report Second Quarter 2025 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2025 financial results on ...
Orthofix Announces Global Commercial Launch of the TrueLok Elevate Transverse Bone Transport System
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the global commercial launch of the TrueLok™ Elevate Transverse Bo...
Orthofix Medical Earnings Call Transcript: Q1 2025
Q1 2025 saw 6% net sales growth and 200 bps EBITDA margin expansion, led by strong orthopedics and bone growth therapies. Full-year guidance projects 5% sales growth and continued margin improvement, with positive free cash flow expected.
Orthofix Reports First Quarter 2025 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, u...
Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) cle...